Hologic (HOLX) Stock Analysis & Winston Score
Hologic is a medical device and diagnostics company focused almost entirely on women's health. Its main products include mammography machines that screen for breast cancer, tests that detect cervical cancer and sexually transmitted infections, and surgical tools used in minimally invasive gynecological procedures. Hospitals, clinics, and doctors' offices across the United States are its primary customers. Hologic makes money by selling its imaging equipment and then generating recurring revenue from the disposable supplies, test kits, and software those machines require. Most of its revenue comes from the U.S., though it has a meaningful international presence through its diagnostics segment. The company's moat comes partly from its dominant position in 3D mammography, where its Genius platform holds strong market share, and from long-term customer relationships built around proprietary consumables. The key risk is that COVID-19 testing once inflated its diagnostics revenue significantly, and sustaining growth now depends on expanding its core women's health business as that tailwind fades.
Winston Score: 48/100 — Average
Mixed quality — meaningful strengths and weaknesses.
- Quality: Good (17/30)
- Growth: Weak (4/20)
- Cash Flow: Exceptional (10/10)
- Stability: Strong (7/10)
- Valuation: Good (6/10)
- Ownership: Weak (2/15)
Key Facts
Price: $76.01
Market Cap: $17.0B
Sector: Healthcare
Industry: Medical - Instruments & Supplies



